Chapter·Prescribing, Ethics & Patient SafetySafe Prescribing

High-risk medicinesDownloads

10Questions
10Flashcards
4Tables & Flowcharts

Study Materials

Practice

Sample Questions

1

A 28-year-old woman presents with a 3-day history of dysuria, urinary frequency, and suprapubic pain. She is otherwise well with no fever. Urine dipstick shows nitrites positive, leucocytes positive. What is the most appropriate first-line antibiotic treatment?

AAmoxicillin 500mg TDS for 7 days

BTrimethoprim 200mg BD for 3 days

CCiprofloxacin 500mg BD for 7 days

DNitrofurantoin 50mg QDS for 3 days

ECo-amoxiclav 625mg TDS for 7 days

2

A 59-year-old man with type 1 diabetes for 25 years is admitted with acute pancreatitis. His usual insulin regimen is insulin glargine 32 units at bedtime and insulin lispro 8 units with meals. He is kept nil by mouth and started on intravenous fluids. His admission glucose is 16.2 mmol/L. According to best practice for managing insulin in acute illness with nil-by-mouth status, what is the most appropriate insulin management?

AContinue insulin glargine at usual dose; omit insulin lispro while nil by mouth

BContinue insulin glargine; give insulin lispro based on blood glucose readings every 4 hours

CStop all insulin until he is eating and drinking again

DConvert to variable-rate intravenous insulin infusion at 0.05 units/kg/hour

EGive half the usual total daily insulin dose as basal insulin only

3

A 68-year-old woman with non-valvular atrial fibrillation (CHA₂DS₂-VASc score 4) is on apixaban 5mg twice daily. She is diagnosed with intermediate-risk myelodysplastic syndrome requiring treatment with azacitidine chemotherapy, which carries significant thrombocytopenia risk (expected platelet nadir 20-50 × 10⁹/L). What is the most appropriate anticoagulation strategy during chemotherapy?

AContinue apixaban 5mg twice daily throughout chemotherapy; monitor platelets weekly

BReduce apixaban to 2.5mg twice daily during chemotherapy cycles

CSwitch to prophylactic-dose LMWH during chemotherapy cycles

DSwitch to warfarin with target INR 2-3 as it can be more easily reversed

ETemporarily stop all anticoagulation during chemotherapy cycles; restart when platelets >50 × 10⁹/L

+ 7 more in the PDF

More Safe Prescribing downloads

Browse all chapters

View all